|
G |
A1bg |
alpha-1-B glycoprotein |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of A1BG protein |
CTD |
PMID:25821032 |
|
NCBI chr 7:92,493,934...92,498,460
Ensembl chr 7:92,494,372...92,498,097
|
|
G |
A2m |
alpha-2-macroglobulin |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of A2M protein |
CTD |
PMID:25821032 |
|
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
olanzapine results in decreased activity of ABCB11 protein |
CTD |
PMID:22646477 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases activity multiple interactions |
ISO EXP |
olanzapine results in decreased activity of ABCB1 protein [[ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] affects the susceptibility to Fluoxetine] which affects the abundance of Olanzapine; [[ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] affects the susceptibility to Fluoxetine] which results in increased uptake of Olanzapine; [ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] results in increased abundance of and results in decreased uptake of Olanzapine |
CTD |
PMID:16810505 PMID:34610281 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
multiple interactions |
EXP |
[[ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] affects the susceptibility to Fluoxetine] which affects the abundance of Olanzapine; [[ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] affects the susceptibility to Fluoxetine] which results in increased uptake of Olanzapine; [ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] results in increased abundance of and results in decreased uptake of Olanzapine |
CTD |
PMID:34610281 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
olanzapine inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone] |
CTD |
PMID:18834354 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
decreases expression multiple interactions |
ISO |
Olanzapine results in decreased expression of ACACA mRNA capsazepine inhibits the reaction [Olanzapine results in decreased expression of ACACA mRNA]; Metformin inhibits the reaction [Olanzapine results in decreased expression of ACACA mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in decreased expression of ACACA mRNA] |
CTD |
PMID:32652086 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
EXP |
[olanzapine co-treated with 1-(carboxymethylthio)tetradecane] results in increased activity of ACOX1 protein; [olanzapine co-treated with 1-(carboxymethylthio)tetradecane] results in increased expression of ACOX1 mRNA |
CTD |
PMID:23226405 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Adcyap1r1 |
ADCYAP receptor type I |
affects expression |
ISO |
olanzapine affects the expression of ADCYAP1R1 mRNA |
CTD |
PMID:27900577 |
|
NCBI chr 4:84,593,558...84,642,700
Ensembl chr 4:84,593,892...84,642,700
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression multiple interactions decreases expression |
ISO |
olanzapine results in increased expression of ADIPOQ mRNA capsazepine inhibits the reaction [Olanzapine results in decreased expression of ADIPOQ protein]; Metformin inhibits the reaction [Olanzapine results in decreased expression of ADIPOQ protein]; Ruthenium Red inhibits the reaction [Olanzapine results in decreased expression of ADIPOQ protein] |
CTD |
PMID:17651982 PMID:32652086 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Afm |
afamin |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of AFM protein |
CTD |
PMID:25821032 |
|
NCBI chr14:17,531,022...17,563,868
Ensembl chr14:17,531,024...17,563,870
|
|
G |
Agrp |
agouti related neuropeptide |
increases expression multiple interactions |
EXP ISO |
olanzapine results in increased expression of AGRP protein Olanzapine results in increased expression of AGRP mRNA Metformin inhibits the reaction [Olanzapine results in increased expression of AGRP mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of AGRP mRNA] |
CTD |
PMID:21695181 PMID:32652086 |
|
NCBI chr19:33,447,992...33,481,602
Ensembl chr19:33,447,992...33,449,584
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases expression increases phosphorylation increases response to substance multiple interactions decreases expression |
ISO |
Olanzapine results in increased expression of AKT1 mRNA; Olanzapine results in increased expression of AKT1 protein olanzapine results in increased phosphorylation of AKT1 protein AKT1 gene SNP results in increased susceptibility to olanzapine capsazepine inhibits the reaction [Olanzapine results in decreased expression of AKT1 mRNA]; Metformin inhibits the reaction [Olanzapine results in decreased expression of AKT1 mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in decreased expression of AKT1 mRNA] |
CTD |
PMID:19440698 PMID:21187413 PMID:32652086 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of ALB protein |
CTD |
PMID:25821032 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases phosphorylation |
ISO |
olanzapine results in increased phosphorylation of APOA1 protein |
CTD |
PMID:25821032 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoa4 |
apolipoprotein A4 |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of APOA4 protein |
CTD |
PMID:25821032 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Apob |
apolipoprotein B |
increases phosphorylation |
ISO |
olanzapine results in increased phosphorylation of APOB protein |
CTD |
PMID:25821032 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoc3 |
apolipoprotein C3 |
affects response to substance |
EXP |
APOC3 gene polymorphism affects the susceptibility to olanzapine |
CTD |
PMID:17726453 |
|
NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583
|
|
G |
Apoh |
apolipoprotein H |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of APOH protein |
CTD |
PMID:25821032 |
|
NCBI chr10:93,342,435...93,356,334
Ensembl chr10:93,310,977...93,356,329
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
olanzapine inhibits the reaction [APP protein modified form affects the activity of CAT protein]; olanzapine inhibits the reaction [APP protein modified form results in increased abundance of Reactive Oxygen Species] |
CTD |
PMID:15948179 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp4 |
aquaporin 4 |
affects response to substance increases response to substance |
ISO |
AQP4 gene polymorphism affects the susceptibility to olanzapine AQP4 protein results in increased susceptibility to olanzapine |
CTD |
PMID:22544010 |
|
NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
olanzapine results in increased expression of BAX protein |
CTD |
PMID:16462815 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression |
EXP |
olanzapine inhibits the reaction [Methamphetamine results in decreased expression of BCL2 protein] olanzapine results in increased expression of BCL2 mRNA; olanzapine results in increased expression of BCL2 protein |
CTD |
PMID:15126120 PMID:15276877 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
EXP ISO |
olanzapine results in increased expression of BDNF mRNA; olanzapine results in increased expression of BDNF protein Olanzapine results in increased expression of BDNF mRNA; Olanzapine results in increased expression of BDNF protein |
CTD |
PMID:12478621 PMID:17442489 PMID:29182611 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bik |
BCL2-interacting killer |
increases expression |
ISO |
olanzapine results in increased expression of BIK mRNA |
CTD |
PMID:16160616 |
|
NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
|
|
G |
C3 |
complement C3 |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of C3 protein |
CTD |
PMID:25821032 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
C4a |
complement C4A |
decreases phosphorylation |
ISO |
olanzapine results in decreased phosphorylation of C4A protein |
CTD |
PMID:25821032 |
|
NCBI chr20:4,005,731...4,020,083
Ensembl chr20:4,005,731...4,020,080
|
|
G |
C4b |
complement C4B |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of C4B protein |
CTD |
PMID:25821032 |
|
NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681
|
|
G |
C5 |
complement C5 |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of C5 protein |
CTD |
PMID:25821032 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
C6 |
complement C6 |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of C6 protein |
CTD |
PMID:25821032 |
|
NCBI chr 2:53,846,028...53,921,279
Ensembl chr 2:53,851,985...53,921,275
|
|
G |
C9 |
complement C9 |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of C9 protein |
CTD |
PMID:25821032 |
|
NCBI chr 2:55,573,094...55,621,345
Ensembl chr 2:55,572,992...55,621,338
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions |
EXP |
olanzapine results in decreased expression of and results in decreased phosphorylation of CAMK2A protein |
CTD |
PMID:18061412 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
olanzapine inhibits the reaction [APP protein modified form affects the activity of CAT protein] |
CTD |
PMID:15948179 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cfb |
complement factor B |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of CFB protein |
CTD |
PMID:25821032 |
|
NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505
|
|
G |
Cfh |
complement factor H |
decreases phosphorylation |
ISO |
olanzapine results in decreased phosphorylation of CFH protein |
CTD |
PMID:25821032 |
|
NCBI chr13:51,512,376...51,613,829
Ensembl chr13:51,511,828...51,613,838
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
affects binding |
ISO |
olanzapine binds to CHRM1 protein |
CTD |
PMID:16983399 |
|
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Clu |
clusterin |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of CLU protein |
CTD |
PMID:25821032 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases phosphorylation |
ISO |
olanzapine results in decreased phosphorylation of COL1A1 protein |
CTD |
PMID:25821032 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Comt |
catechol-O-methyltransferase |
increases expression |
EXP |
olanzapine results in increased expression of COMT mRNA |
CTD |
PMID:15964593 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cp |
ceruloplasmin |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of CP protein |
CTD |
PMID:25821032 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
EXP |
[olanzapine co-treated with 1-(carboxymethylthio)tetradecane] results in decreased expression of CPT2 mRNA; [olanzapine co-treated with 1-(carboxymethylthio)tetradecane] results in increased activity of CPT2 protein; [olanzapine co-treated with 1-(carboxymethylthio)tetradecane] results in increased expression of CPT2 mRNA |
CTD |
PMID:23226405 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
[Fluoxetine co-treated with olanzapine] results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:14556240 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cs |
citrate synthase |
increases activity multiple interactions |
EXP |
Olanzapine results in increased activity of CS protein [Olanzapine co-treated with Fluoxetine] results in increased activity of CS protein |
CTD |
PMID:20971158 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression multiple interactions increases expression |
ISO |
olanzapine results in decreased expression of CTNNB1 mRNA Olanzapine inhibits the reaction [Dizocilpine Maleate results in decreased expression of CTNNB1 mRNA] Olanzapine results in increased expression of CTNNB1 mRNA |
CTD |
PMID:18797397 PMID:31563592 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects metabolic processing multiple interactions |
ISO |
CYP1A2 protein affects the metabolism of olanzapine Fluvoxamine inhibits the reaction [CYP1A2 protein affects the metabolism of olanzapine] |
CTD |
PMID:15545309 PMID:15883149 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Dab1 |
DAB adaptor protein 1 |
decreases expression |
EXP |
olanzapine results in decreased expression of DAB1 protein |
CTD |
PMID:19359144 |
|
NCBI chr 5:118,392,953...119,513,625
Ensembl chr 5:119,140,533...119,510,552
|
|
G |
Dclk1 |
doublecortin-like kinase 1 |
increases expression |
ISO |
olanzapine results in increased expression of DCLK1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 2:139,417,234...139,710,956
Ensembl chr 2:139,417,163...139,710,956
|
|
G |
Drd1 |
dopamine receptor D1 |
affects binding |
ISO |
olanzapine binds to DRD1 protein |
CTD |
PMID:24389121 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
increases response to substance affects activity affects binding decreases activity multiple interactions |
ISO EXP |
DRD2 gene SNP results in increased susceptibility to olanzapine; DRD2 intron SNP results in increased susceptibility to olanzapine olanzapine affects the activity of DRD2 protein olanzapine binds to DRD2 protein olanzapine results in decreased activity of DRD2 protein olanzapine promotes the reaction [Dopamine binds to DRD2 protein] |
CTD |
PMID:10482380 PMID:10831489 PMID:11198054 PMID:15716360 PMID:20361897 PMID:20375926 PMID:21187413 PMID:24389121 More...
|
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd3 |
dopamine receptor D3 |
multiple interactions |
ISO |
DRD3 protein results in increased susceptibility to [olanzapine co-treated with Fluoxetine] |
CTD |
PMID:20021991 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
F2 |
coagulation factor II, thrombin |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of F2 protein |
CTD |
PMID:25821032 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
increases expression |
ISO |
Olanzapine results in increased expression of FABP1 mRNA |
CTD |
PMID:31437515 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
olanzapine results in increased expression of FASN mRNA |
CTD |
PMID:17651982 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
EXP |
[Fluoxetine co-treated with olanzapine] results in increased expression of FGF2 mRNA |
CTD |
PMID:15158429 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fn1 |
fibronectin 1 |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of FN1 protein |
CTD |
PMID:25821032 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[Fluoxetine co-treated with olanzapine] results in decreased expression of FOS protein |
CTD |
PMID:14556240 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions |
EXP |
olanzapine inhibits the reaction [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased expression of FOSL1 protein] |
CTD |
PMID:11425506 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
decreases expression |
EXP |
olanzapine results in decreased expression of GAD1 mRNA; olanzapine results in decreased expression of GAD1 protein |
CTD |
PMID:14519413 PMID:19359144 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gad2 |
glutamate decarboxylase 2 |
decreases expression |
EXP |
olanzapine results in decreased expression of GAD2 protein |
CTD |
PMID:19359144 |
|
NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155
|
|
G |
Gc |
GC, vitamin D binding protein |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of GC protein |
CTD |
PMID:25821032 |
|
NCBI chr14:18,632,146...18,667,563
Ensembl chr14:18,632,135...18,667,567
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
Olanzapine results in increased expression of GCLC mRNA |
CTD |
PMID:37005277 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions increases expression |
ISO |
capsazepine inhibits the reaction [Olanzapine results in increased expression of GFAP mRNA]; Metformin inhibits the reaction [Olanzapine results in increased expression of GFAP mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of GFAP mRNA] |
CTD |
PMID:32652086 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Ghrl |
ghrelin and obestatin prepropeptide |
multiple interactions increases expression |
ISO |
capsazepine inhibits the reaction [Olanzapine results in increased expression of GHRL protein]; Metformin inhibits the reaction [Olanzapine results in increased expression of GHRL protein]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of GHRL protein] |
CTD |
PMID:32652086 |
|
NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621
|
|
G |
Ghsr |
growth hormone secretagogue receptor |
increases expression multiple interactions |
ISO |
Olanzapine results in increased expression of GHSR mRNA capsazepine inhibits the reaction [Olanzapine results in increased expression of GHSR mRNA]; Metformin inhibits the reaction [Olanzapine results in increased expression of GHSR mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of GHSR mRNA] |
CTD |
PMID:32652086 |
|
NCBI chr 2:110,268,489...110,271,865
Ensembl chr 2:110,268,489...110,271,865
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions increases expression |
ISO |
Dietary Fats promotes the reaction [Olanzapine results in increased expression of GPT protein] |
CTD |
PMID:37019375 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
increases expression |
EXP |
olanzapine results in increased expression of GRIA2 mRNA |
CTD |
PMID:11526992 |
|
NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
|
|
G |
Gria3 |
glutamate ionotropic receptor AMPA type subunit 3 |
increases expression |
EXP |
olanzapine results in increased expression of GRIA3 mRNA |
CTD |
PMID:11526992 |
|
NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation decreases expression multiple interactions |
ISO |
olanzapine results in increased phosphorylation of GSK3B protein Olanzapine results in decreased expression of GSK3B mRNA Olanzapine inhibits the reaction [Dizocilpine Maleate results in increased expression of GSK3B mRNA] |
CTD |
PMID:19440698 PMID:31563592 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression multiple interactions decreases expression |
ISO EXP |
olanzapine results in increased expression of HMGCR mRNA 1-(carboxymethylthio)tetradecane promotes the reaction [olanzapine results in decreased expression of HMGCR mRNA]; olanzapine promotes the reaction [1-(carboxymethylthio)tetradecane results in decreased expression of HMGCR mRNA] |
CTD |
PMID:17052361 PMID:23226405 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
olanzapine results in increased expression of HMGCS1 mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Olanzapine results in increased expression of HMOX1 mRNA |
CTD |
PMID:37005277 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hpx |
hemopexin |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of HPX protein |
CTD |
PMID:25821032 |
|
NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328
|
|
G |
Hrg |
histidine-rich glycoprotein |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of HRG protein |
CTD |
PMID:25821032 |
|
NCBI chr11:78,054,488...78,069,402
Ensembl chr11:78,054,498...78,069,389
|
|
G |
Hrh1 |
histamine receptor H 1 |
affects binding multiple interactions |
ISO |
olanzapine binds to HRH1 protein HRH1 protein results in increased susceptibility to [olanzapine co-treated with Fluoxetine] |
CTD |
PMID:16983399 PMID:20021991 PMID:24389121 |
|
NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
multiple interactions affects binding decreases activity |
ISO EXP |
olanzapine binds to and results in decreased activity of HTR2A protein olanzapine binds to HTR2A protein [[olanzapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein] which results in increased expression of RGS7 protein; [alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide results in decreased activity of JAK2 protein] inhibits the reaction [olanzapine results in decreased activity of HTR2A protein]; [olanzapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein; olanzapine binds to and results in decreased activity of HTR2A protein |
CTD |
PMID:16983399 PMID:18976543 PMID:19304867 PMID:20521326 PMID:24389121 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Htr2c |
5-hydroxytryptamine receptor 2C |
increases response to substance affects response to substance affects binding |
ISO |
HTR2C gene polymorphism results in increased susceptibility to olanzapine HTR2C gene polymorphism affects the susceptibility to Olanzapine; HTR2C gene SNP affects the susceptibility to Olanzapine; HTR2C protein affects the susceptibility to Olanzapine olanzapine binds to HTR2C protein |
CTD |
PMID:15666332 PMID:16983399 PMID:19142110 PMID:19434072 PMID:24389121 |
|
NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287
|
|
G |
Htr6 |
5-hydroxytryptamine receptor 6 |
affects binding |
ISO |
olanzapine binds to HTR6 protein |
CTD |
PMID:16983399 |
|
NCBI chr 5:151,295,269...151,312,853
Ensembl chr 5:151,296,662...151,311,912
|
|
G |
Il10 |
interleukin 10 |
increases expression multiple interactions decreases expression |
ISO |
Olanzapine results in increased expression of IL10 mRNA Lithium inhibits the reaction [Olanzapine results in decreased expression of IL10 protein] |
CTD |
PMID:30695037 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO |
Lithium inhibits the reaction [Olanzapine results in increased expression of IL1B mRNA]; Lithium inhibits the reaction [Olanzapine results in increased expression of IL1B protein] Olanzapine results in increased expression of IL1B mRNA; Olanzapine results in increased expression of IL1B protein |
CTD |
PMID:30695037 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
capsazepine inhibits the reaction [Olanzapine results in increased expression of IL6 protein]; Lithium inhibits the reaction [Olanzapine results in increased expression of IL6 mRNA]; Lithium inhibits the reaction [Olanzapine results in increased expression of IL6 protein]; Metformin inhibits the reaction [Olanzapine results in increased expression of IL6 protein]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of IL6 protein] Olanzapine results in increased expression of IL6 mRNA; Olanzapine results in increased expression of IL6 protein |
CTD |
PMID:30695037 PMID:32652086 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
increases secretion increases expression |
ISO |
olanzapine results in increased secretion of INS protein olanzapine results in increased expression of INS protein |
CTD |
PMID:11769361 PMID:11927762 PMID:16601995 PMID:19512971 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Itih2 |
inter-alpha-trypsin inhibitor heavy chain 2 |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of ITIH2 protein |
CTD |
PMID:25821032 |
|
NCBI chr17:68,375,574...68,411,849
Ensembl chr17:68,375,567...68,411,841
|
|
G |
Itih4 |
inter-alpha-trypsin inhibitor heavy chain 4 |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of ITIH4 protein |
CTD |
PMID:25821032 |
|
NCBI chr16:6,080,539...6,095,710
Ensembl chr16:6,080,539...6,095,708
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions increases activity |
EXP |
[[olanzapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein] which results in increased expression of RGS7 protein; [alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide results in decreased activity of JAK2 protein] inhibits the reaction [olanzapine results in decreased activity of HTR2A protein]; [alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide results in decreased activity of JAK2 protein] inhibits the reaction [olanzapine results in increased expression of RGS7 mRNA]; [alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide results in decreased activity of JAK2 protein] inhibits the reaction [olanzapine results in increased expression of RGS7 protein]; [olanzapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein olanzapine results in increased activity of JAK2 protein |
CTD |
PMID:18976543 PMID:19304867 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Kcna1 |
potassium voltage-gated channel subfamily A member 1 |
increases expression |
ISO |
olanzapine results in increased expression of KCNA1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 4:159,464,223...159,472,905
Ensembl chr 4:159,464,188...159,472,682
|
|
G |
Kcnab1 |
potassium voltage-gated channel subfamily A regulatory beta subunit 1 |
decreases expression |
ISO |
olanzapine results in decreased expression of KCNAB1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 2:149,137,025...149,603,540
Ensembl chr 2:149,137,041...149,603,534
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity multiple interactions |
ISO |
olanzapine results in decreased activity of KCNH2 protein olanzapine inhibits the reaction [KCNH2 protein results in increased transport of Thallium] |
CTD |
PMID:16494862 PMID:21158687 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnip3 |
potassium voltage-gated channel interacting protein 3 |
decreases expression |
ISO |
olanzapine results in decreased expression of KCNIP3 mRNA; olanzapine results in decreased expression of KCNIP3 protein |
CTD |
PMID:18797397 |
|
NCBI chr 3:114,677,027...114,742,923
Ensembl chr 3:114,677,030...114,743,556
|
|
G |
Klc1 |
kinesin light chain 1 |
decreases expression |
ISO |
olanzapine results in decreased expression of KLC1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 6:130,823,416...130,866,729
Ensembl chr 6:130,823,419...130,867,031
|
|
G |
Kng1 |
kininogen 1 |
affects phosphorylation |
ISO |
Olanzapine affects the phosphorylation of KNG1 protein |
CTD |
PMID:25821032 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression multiple interactions |
ISO |
olanzapine results in increased expression of LDLR mRNA olanzapine promotes the reaction [SREBF1 protein results in increased expression of LDLR mRNA] |
CTD |
PMID:17052361 PMID:17651982 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
increases expression multiple interactions |
ISO |
olanzapine results in increased expression of LEP protein capsazepine inhibits the reaction [Olanzapine results in increased expression of LEP protein]; Metformin inhibits the reaction [Olanzapine results in increased expression of LEP protein]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of LEP protein] |
CTD |
PMID:11927762 PMID:19512971 PMID:32652086 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Mal |
mal, T-cell differentiation protein |
decreases expression |
ISO |
olanzapine results in decreased expression of MAL mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 3:114,864,378...114,888,136
Ensembl chr 3:114,864,378...114,888,136
|
|
G |
Maoa |
monoamine oxidase A |
increases expression |
EXP |
olanzapine results in increased expression of MAOA mRNA |
CTD |
PMID:15964593 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Maob |
monoamine oxidase B |
increases expression |
EXP |
olanzapine results in increased expression of MAOB mRNA |
CTD |
PMID:15964593 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
EXP |
olanzapine results in increased expression of MAP2 mRNA |
CTD |
PMID:15079866 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
increases expression |
EXP |
Olanzapine results in increased expression of MKI67 protein |
CTD |
PMID:38437955 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mthfr |
methylenetetrahydrofolate reductase |
affects response to substance |
ISO |
MTHFR gene polymorphism affects the susceptibility to olanzapine; MTHFR protein affects the susceptibility to olanzapine |
CTD |
PMID:20547447 |
|
NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797
|
|
G |
Ncan |
neurocan |
decreases expression |
ISO |
olanzapine results in decreased expression of NCAN mRNA |
CTD |
PMID:18797397 |
|
NCBI chr16:19,301,969...19,328,436
Ensembl chr16:19,301,969...19,328,436
|
|
G |
Nedd4 |
NEDD4 E3 ubiquitin protein ligase |
decreases expression |
ISO |
olanzapine results in decreased expression of NEDD4 mRNA; olanzapine results in decreased expression of NEDD4 protein |
CTD |
PMID:18797397 |
|
NCBI chr 8:73,384,095...73,468,951
Ensembl chr 8:73,383,695...73,468,951
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases expression |
ISO |
Olanzapine results in decreased expression of NFE2L2 protein |
CTD |
PMID:37019375 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions increases expression |
ISO |
capsazepine inhibits the reaction [Olanzapine results in increased expression of NFKB1 mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of NFKB1 mRNA] |
CTD |
PMID:32652086 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nptn |
neuroplastin |
increases expression |
ISO |
olanzapine results in increased expression of NPTN mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 8:58,996,873...59,063,402
Ensembl chr 8:58,996,887...59,063,401
|
|
G |
Npy |
neuropeptide Y |
decreases expression increases expression multiple interactions |
EXP ISO |
olanzapine results in decreased expression of NPY mRNA olanzapine results in increased expression of NPY protein capsazepine inhibits the reaction [Olanzapine results in increased expression of NPY mRNA]; Metformin inhibits the reaction [Olanzapine results in increased expression of NPY mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of NPY mRNA] |
CTD |
PMID:16516965 PMID:21695181 PMID:32652086 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Numbl |
NUMB-like, endocytic adaptor protein |
decreases expression |
ISO |
olanzapine results in decreased expression of NUMBL mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 1:82,549,814...82,573,788
Ensembl chr 1:82,550,054...82,573,776
|
|
G |
Pde1a |
phosphodiesterase 1A |
increases expression |
EXP |
olanzapine results in increased expression of PDE1A mRNA |
CTD |
PMID:20222156 |
|
NCBI chr 3:64,745,140...65,025,178
Ensembl chr 3:64,747,269...65,024,874
|
|
G |
Pde8b |
phosphodiesterase 8B |
increases expression |
EXP |
olanzapine results in increased expression of PDE8B mRNA |
CTD |
PMID:20222156 |
|
NCBI chr 2:26,275,117...26,479,725
Ensembl chr 2:26,276,635...26,509,209
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions decreases expression |
ISO |
capsazepine inhibits the reaction [Olanzapine results in decreased expression of PIK3R1 mRNA]; Metformin inhibits the reaction [Olanzapine results in decreased expression of PIK3R1 mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in decreased expression of PIK3R1 mRNA] |
CTD |
PMID:32652086 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Plac8 |
placenta associated 8 |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of C15 protein |
CTD |
PMID:25821032 |
|
NCBI chr14:9,052,601...9,074,264
Ensembl chr14:9,063,048...9,074,264
|
|
G |
Plp1 |
proteolipid protein 1 |
decreases expression |
ISO |
olanzapine results in decreased expression of PLP1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr X:100,184,039...100,201,035
Ensembl chr X:100,185,767...100,201,032
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
affects expression |
EXP |
olanzapine affects the expression of PNPLA2 mRNA |
CTD |
PMID:23226405 |
|
NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805
|
|
G |
Pomc |
proopiomelanocortin |
decreases expression multiple interactions |
EXP ISO |
olanzapine results in decreased expression of POMC protein capsazepine inhibits the reaction [Olanzapine results in decreased expression of POMC mRNA]; Metformin inhibits the reaction [Olanzapine results in decreased expression of POMC mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in decreased expression of POMC mRNA] |
CTD |
PMID:21695181 PMID:32652086 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
olanzapine results in increased expression of PPARG protein alternative form |
CTD |
PMID:17651982 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression multiple interactions |
EXP |
olanzapine results in decreased expression of PPARGC1A mRNA [olanzapine co-treated with 1-(carboxymethylthio)tetradecane] results in decreased expression of PPARGC1A mRNA; olanzapine promotes the reaction [1-(carboxymethylthio)tetradecane results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:23226405 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkag2 |
protein kinase AMP-activated non-catalytic subunit gamma 2 |
increases expression multiple interactions |
ISO |
Olanzapine results in increased expression of PRKAG2 mRNA capsazepine inhibits the reaction [Olanzapine results in increased expression of PRKAG2 mRNA]; Metformin inhibits the reaction [Olanzapine results in increased expression of PRKAG2 mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of PRKAG2 mRNA] |
CTD |
PMID:32652086 |
|
NCBI chr 4:10,010,890...10,252,155
Ensembl chr 4:10,010,890...10,252,142
|
|
G |
Prl |
prolactin |
multiple interactions increases expression increases secretion |
ISO EXP |
[olanzapine co-treated with Fluoxetine] results in increased expression of PRL protein olanzapine results in increased expression of PRL protein olanzapine results in increased secretion of PRL protein Bromocriptine inhibits the reaction [Olanzapine results in increased expression of PRL protein] |
CTD |
PMID:9090331 PMID:9265911 PMID:9376336 PMID:10831029 PMID:11048906 PMID:11442886 PMID:12447030 PMID:15286066 PMID:15960571 PMID:18063941 PMID:19896213 PMID:38437955 More...
|
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prlr |
prolactin receptor |
increases expression |
EXP |
Olanzapine results in increased expression of PRLR mRNA; Olanzapine results in increased expression of PRLR protein |
CTD |
PMID:38437955 |
|
NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:59,134,588...59,324,718
|
|
G |
Prrc2a |
proline-rich coiled-coil 2A |
decreases expression |
ISO |
olanzapine results in decreased expression of PRRC2A mRNA |
CTD |
PMID:18797397 |
|
NCBI chr20:3,658,391...3,674,143
Ensembl chr20:3,658,695...3,674,130
|
|
G |
Rapgef4 |
Rap guanine nucleotide exchange factor 4 |
decreases expression |
ISO |
olanzapine results in decreased expression of RAPGEF4 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 3:56,809,388...57,101,332
Ensembl chr 3:56,809,270...57,102,316
|
|
G |
Reln |
reelin |
increases expression |
EXP |
olanzapine results in increased expression of RELN mRNA; olanzapine results in increased expression of RELN protein |
CTD |
PMID:19359144 |
|
NCBI chr 4:12,736,177...13,162,956
Ensembl chr 4:12,736,130...13,162,211
|
|
G |
Rgs7 |
regulator of G-protein signaling 7 |
multiple interactions increases expression |
EXP |
[[Olanzapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein] which results in increased expression of RGS7 protein; [alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide results in decreased activity of JAK2 protein] inhibits the reaction [Olanzapine results in increased expression of RGS7 mRNA]; [alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide results in decreased activity of JAK2 protein] inhibits the reaction [Olanzapine results in increased expression of RGS7 protein]; Olanzapine promotes the reaction [[STAT3 protein binds to RGS7 promoter] which results in increased expression of RGS7 mRNA]; Olanzapine promotes the reaction [STAT3 protein binds to RGS7 promoter] olanzapine results in increased expression of RGS7 mRNA; olanzapine results in increased expression of RGS7 protein |
CTD |
PMID:18976543 PMID:19304867 |
|
NCBI chr13:86,979,269...87,408,834
Ensembl chr13:86,979,279...87,408,888
|
|
G |
Rtn4 |
reticulon 4 |
decreases expression |
ISO |
olanzapine results in decreased expression of RTN4 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr14:103,450,074...103,497,687
Ensembl chr14:103,449,930...103,497,686
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
decreases expression |
ISO |
olanzapine results in decreased expression of S100A9 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Sc5d |
sterol-C5-desaturase |
increases expression |
ISO |
olanzapine results in increased expression of SC5D mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 8:42,629,649...42,641,257
Ensembl chr 8:42,632,672...42,641,273
|
|
G |
Serpina3n |
serpin family A member 3N |
increases phosphorylation |
ISO |
Olanzapine results in increased phosphorylation of SERPINA3 protein |
CTD |
PMID:25821032 |
|
NCBI chr 6:123,323,623...123,331,181
Ensembl chr 6:123,323,629...123,332,433
|
|
G |
Serping1 |
serpin family G member 1 |
affects phosphorylation |
ISO |
olanzapine affects the phosphorylation of SERPING1 protein |
CTD |
PMID:25821032 |
|
NCBI chr 3:69,842,726...69,852,583
Ensembl chr 3:69,842,739...69,852,034
|
|
G |
Serpini1 |
serpin family I member 1 |
decreases expression |
ISO |
olanzapine results in decreased expression of SERPINI1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 2:160,346,403...160,433,135
Ensembl chr 2:160,346,758...160,433,135
|
|
G |
Shbg |
sex hormone binding globulin |
decreases expression |
ISO |
olanzapine results in decreased expression of SHBG protein |
CTD |
PMID:19512971 |
|
NCBI chr10:54,332,939...54,350,409
Ensembl chr10:54,332,941...54,351,057
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
olanzapine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
decreases expression multiple interactions |
ISO |
Olanzapine results in decreased expression of SLC22A5 mRNA; Olanzapine results in decreased expression of SLC22A5 protein Olanzapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine analog] |
CTD |
PMID:31437515 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc27a2 |
solute carrier family 27 member 2 |
increases expression |
ISO |
Olanzapine results in increased expression of SLC27A2 mRNA |
CTD |
PMID:31437515 |
|
NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208
|
|
G |
Slc27a5 |
solute carrier family 27 member 5 |
increases expression |
ISO |
Olanzapine results in increased expression of SLC27A5 mRNA |
CTD |
PMID:31437515 |
|
NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression |
ISO |
olanzapine results in increased expression of SLC2A4 mRNA |
CTD |
PMID:16002093 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
decreases expression |
ISO |
Olanzapine results in decreased expression of SLC7A11 mRNA |
CTD |
PMID:37005277 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Snap25 |
synaptosome associated protein 25 |
affects response to substance |
ISO |
SNAP25 gene SNP affects the susceptibility to olanzapine |
CTD |
PMID:15823421 |
|
NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions increases expression decreases activity |
EXP ISO |
olanzapine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SOD1 mRNA]; olanzapine inhibits the reaction [Haloperidol results in decreased expression of SOD1 protein]; olanzapine inhibits the reaction [Hydrogen Peroxide results in decreased expression of SOD1 mRNA] olanzapine results in increased expression of SOD1 mRNA Dietary Fats promotes the reaction [Olanzapine results in decreased activity of SOD1 protein] |
CTD |
PMID:12752374 PMID:12868070 PMID:16564057 PMID:37019375 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions increases expression |
ISO |
olanzapine promotes the reaction [SREBF1 protein results in increased expression of LDLR mRNA]; olanzapine results in increased activity of and results in increased expression of SREBF1 protein olanzapine results in increased expression of SREBF1 mRNA |
CTD |
PMID:17651982 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO EXP |
olanzapine results in increased cleavage of and results in increased activity of SREBF2 protein [olanzapine co-treated with 1-(carboxymethylthio)tetradecane] results in decreased expression of SREBF2 mRNA |
CTD |
PMID:17052361 PMID:23226405 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
olanzapine promotes the reaction [[STAT3 protein binds to RGS7 promoter] which results in increased expression of RGS7 mRNA]; olanzapine promotes the reaction [STAT3 protein binds to RGS7 promoter] |
CTD |
PMID:18976543 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Sypl1 |
synaptophysin-like 1 |
decreases expression |
ISO |
Olanzapine results in decreased expression of SYPL1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 6:49,565,111...49,585,205
Ensembl chr 6:49,565,154...49,585,330
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
olanzapine inhibits the reaction [Methamphetamine results in decreased expression of TH protein] |
CTD |
PMID:15276877 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO |
capsazepine inhibits the reaction [Olanzapine results in increased expression of TNF protein]; Dietary Fats promotes the reaction [Olanzapine results in increased expression of TNF protein]; Lithium inhibits the reaction [Olanzapine results in increased expression of TNF mRNA]; Lithium inhibits the reaction [Olanzapine results in increased expression of TNF protein]; Metformin inhibits the reaction [Olanzapine results in increased expression of TNF protein]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of TNF protein] Olanzapine results in increased expression of TNF mRNA; Olanzapine results in increased expression of TNF protein |
CTD |
PMID:30695037 PMID:32652086 PMID:37019375 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
olanzapine results in increased expression of TP53 mRNA |
CTD |
PMID:16160616 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases expression |
ISO |
capsazepine inhibits the reaction [Olanzapine results in increased expression of TRPV1 mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of TRPV1 mRNA] |
CTD |
PMID:32652086 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Trpv3 |
transient receptor potential cation channel, subfamily V, member 3 |
multiple interactions increases expression |
ISO |
Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of TRPV3 mRNA] |
CTD |
PMID:32652086 |
|
NCBI chr10:57,883,546...57,915,865
Ensembl chr10:57,883,546...57,913,296
|
|
G |
Ttr |
transthyretin |
increases expression |
EXP |
olanzapine results in increased expression of TTR mRNA |
CTD |
PMID:15927202 |
|
NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions |
EXP |
[olanzapine co-treated with 1-(carboxymethylthio)tetradecane] results in decreased expression of UCP1 mRNA |
CTD |
PMID:23226405 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Vipr2 |
vasoactive intestinal peptide receptor 2 |
affects expression |
ISO |
olanzapine affects the expression of VIPR2 mRNA |
CTD |
PMID:27900577 |
|
NCBI chr 6:136,996,664...137,070,599
Ensembl chr 6:137,001,511...137,070,597
|
|
G |
Vldlr |
very low density lipoprotein receptor |
increases expression |
EXP |
olanzapine results in increased expression of VLDLR protein |
CTD |
PMID:19359144 |
|
NCBI chr 1:224,813,539...224,850,400
Ensembl chr 1:224,814,377...224,845,920
|
|